Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
EXACT Therapeutics AS ( (DE:56F) ) just unveiled an announcement.
EXACT Therapeutics AS has announced its interim results for the first half of 2025, highlighting its ongoing clinical-stage efforts in precision health through Acoustic Cluster Therapy. This announcement underscores the company’s commitment to advancing targeted drug delivery solutions, potentially impacting its market position in oncology and other therapeutic areas.
More about EXACT Therapeutics AS
EXACT Therapeutics is a clinical-stage precision medicine company that leverages ultrasound and microbubbles for targeted drug delivery in oncology and other therapeutic areas. The company’s unique Acoustic Cluster Therapy (ACT®) can be applied to a wide range of therapeutic agents, including those for brain diseases. EXACT Therapeutics is listed on Euronext Growth Oslo under the ticker EXTX.
Average Trading Volume: 28,273
Current Market Cap: NOK120.2M
For a thorough assessment of 56F stock, go to TipRanks’ Stock Analysis page.